Effect of age and single versus multiple dose pharmacokinetics of letrozole (Femara) in breast cancer patients.


Letrozole (trademark Femara) is a new orally active, potent and selective aromatase inhibitor for the hormonal treatment of advanced breast cancer in postmenopausal women. The pharmacokinetics of letrozole and the suppression of peripheral estrogens were studied in 28 breast cancer patients after a single dose and at steady state. The pharmacokinetics of… (More)


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.